| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5827399 | European Journal of Pharmacology | 2015 | 7 Pages |
Abstract
The primary efficacy objective of the study was not met. GSK256073 did not improve HbA1c concentrations at week 12. Despite sustained drug exposure, the ability of the HCA2 agonist to suppress plasma NEFA concentrations waned over time and targeted effects on glucose oxidation and insulin sensitivity subsided.
Keywords
Related Topics
Life Sciences
Neuroscience
Cellular and Molecular Neuroscience
Authors
Robert Dobbins, Robert Byerly, Riley Gaddy, Feng Gao, Kelly Mahar, Antonella Napolitano, Philip Ambery, Anne-Charlotte Le Monnier de Gouville,